DelMar Pharmaceuticals Presents Data

DelMar Pharmaceuticals, a biopharmaceutical company, said early Friday it presented data from its Dianhydrogalactitol (VAL-083) study at the Society for Neuro-Oncology’s 4th Pediatric Neuro-Oncology Basic and Translational Research conference in New York. DelMar has embarked on human clinical trials for VAL-083 across every line of glioblastoma multiforme (GBM) therapy, and has demonstrated clinical activity against a range of cancers in trials sponsored by the U.S. National Cancer Institutes, the company said in a press release.

VAL-083 has been granted an orphan drug designation by the U.S. Food and Drug Administration for the treatment of glioma, medulloblastoma and ovarian cancer, and in Europe for the treatment of malignant gliomas. The company’s presentation entitled “Dianhydrogalactitol (VAL-083) overcomes p53-mediated chemo-resistance and displays synergy with topoisomerase inhibitors” was presented the evening of Thursday, June 15.

Leave a Comment